FindTrial
Sign In

Reference range of 25(OH)VD3 for population with no diabetes, metabolic disorder, chronic hepatic and renal disease in Urumchi community and the change of 25(OH)VD3 in type 2 diabetic patients

The normal range of 25(OH)VD3 for normal population in Urumchi community and the change of 25(OH)VD3 in patients with type 2 diabetes mellitus

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ECS-07000031
Enrollment
Unknown
Registered
2007-11-07
Start date
2007-11-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The 25(OH)VD3 level in type 2 diabetic patients and population with no metabolic disorder

Interventions

Reference group:Nil
II type diabetes group:Nil

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients: in accordance with the WHO diagnosis criteria in 1999; treated by diet therapy, exercise and oral hypoglycemic agents; no insulin treatment;Population with no diabetes, metabolic disorder, chronic hepatic and renal disease: excluding persons with diabetes mellitus, coronary heart disease, hyperlipidemia and diseases influencing the metabolism of serum calcium and vitamin D.

Exclusion criteria

Exclusion criteria: The diseases influencing the metabolism of serum calcium and vitamin D: parathyroid gland diseases, thyroid gland diseases, cushing syndrome, sexual dysfunction, hypopituitarism, metabolic osteopathy, rheumatic osteopathy, malaborption syndrome, history of gastrointestinal surgery, cancer, long term bed rest; The drugs influencing the metabolism of serum calcium and vitamin D: glucocorticosteroid, thyroid hormone, steroid hormone, estrogen, diphosphate, fluorides, thiazine diuretics, vitamin D and its derivatives, calcium agent; Chronic hepatic and renal disease.

Design outcomes

Primary

MeasureTime frame
25(OH)VD3;—

Countries

China

Contacts

Public ContactJun Zhu
zhujun6677@163.com+86 0991-4319117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026